In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT04616248 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8
Unresectable Breast Carcinoma
Metastatic Melanoma
Unresectable Melanoma
Cutaneous Squamous Cell Carcinoma
Merkel Cell Carcinoma
Soft Tissue Sarcoma
Bone Sarcoma
Sarcoma,Soft Tissue
Sarcoma of Bone
Basal Cell Carcinoma

Interventions

BIOLOGICAL: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
DRUG: Poly ICLC
RADIATION: Radiation Therapy
BIOLOGICAL: Recombinant Flt3 Ligand
DRUG: Pembrolizumab
DRUG: Tocilizumab

Sponsor

University of Southern California

Collaborators

[object Object]